Your browser doesn't support javascript.
loading
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.
Qualls, David A; Lambert, Nicholas; Caimi, Paolo F; Merrill, Mwanasha; Pullarkat, Priyanka; Godby, Richard C; Bond, David A; Wehmeyer, Graham T; Romancik, Jason; Amoozgar, Behzad; Leslie, Lori; Nastoupil, Loretta J; Crombie, Jennifer L; Abramson, Jeremy S; Khurana, Arushi; Nowakowski, Grzegorz S; Maddocks, Kami; Rutherford, Sarah C; Kahl, Brad; Okwali, Michelle; Buege, Michael J; Seshan, Venkatraman; Batlevi, Connie L; Salles, Gilles.
Afiliação
  • Qualls DA; Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Lambert N; Department of Medicine, Baylor College of Medicine, Houston, TX.
  • Caimi PF; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH.
  • Merrill M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Pullarkat P; Division of Hematology-Oncology, Massachusetts General Hospital, Boston, MA.
  • Godby RC; Hematology Division, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
  • Bond DA; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH.
  • Wehmeyer GT; Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY.
  • Romancik J; Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA.
  • Amoozgar B; Department of Medicine, Washington University School of Medicine, St Louis, MO.
  • Leslie L; Lymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ.
  • Nastoupil LJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Crombie JL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Abramson JS; Division of Hematology-Oncology, Massachusetts General Hospital, Boston, MA.
  • Khurana A; Hematology Division, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
  • Nowakowski GS; Hematology Division, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
  • Maddocks K; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH.
  • Rutherford SC; Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY.
  • Kahl B; Department of Medicine, Washington University School of Medicine, St Louis, MO.
  • Okwali M; Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Buege MJ; Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Seshan V; Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Batlevi CL; Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Salles G; Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
Blood ; 142(26): 2327-2331, 2023 12 28.
Article em En | MEDLINE | ID: mdl-37738563
ABSTRACT: In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article